Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB (GEN)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
10/13/2017 10/16/2017 10/17/2017 10/18/2017 10/19/2017 Date
1432(c) 1435(c) 1346(c) 1332(c) 1321 Last
152 792 164 780 998 844 745 753 191 126 Volume
+0.56% +0.21% -6.20% -1.04% -0.83% Change
More quotes
Financials ( DKK)
Sales 2017 2 185 M
EBIT 2017 1 149 M
Net income 2017 1 031 M
Finance 2017 4 094 M
Yield 2017 -
Sales 2018 3 500 M
EBIT 2018 2 174 M
Net income 2018 2 090 M
Finance 2018 5 787 M
Yield 2018 0,01%
P/E ratio 2017 78,99
P/E ratio 2018 39,65
EV / Sales2017 35,4x
EV / Sales2018 21,6x
Capitalization 81 469 M
More Financials
Company
Genmab A/S operates as an international biotechnology company.The firm develops human antibody therapeutics for the treatment of cancer.Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX.The company was founded by Lisa N. Drakeman and Jan G. 
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
10/17 GENB ASADR : Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Qua..
10/13 GENMAB : Articles of Association for Genmab A/S
10/12 GENMAB : Studies from Genmab A/S Further Understanding of Sulfides (Cysteine-SIL..
10/12 SEATTLE GENETICS : Genmab and Seattle Genetics to Initiate New Study of Novel An..
10/10 Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conj..
10/10 GENMAB : Grant of Restricted Stock Units and Warrants to Genmab employees
10/05 SEATTLE GENETICS, INC. (NASDAQ : SGEN) Files An 8-K Departure of Directors or Ce..
10/05 GENMAB : Grant of Restricted Stock Units and Warrants to Genmab employees
09/29 GENMAB : Announces Approval of DARZALEX for Relapsed or Refractory Multiple Myel..
09/28 MORPHOSYS : Patent Issued for Method for the Treatment of Multiple Myeloma Or no..
More news
Sector news : Bio Therapeutic Drugs
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/18Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors  
10/18Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors: VI.. 
10/18Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors  
10/17Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 20.. 
10/12Remain bullish #Genmab from 1300 , still think it can go to new ATH and above.. 
More tweets
Qtime:87
News from SeekingAlpha
10/11 YOUR DAILY PHARMA SCOOP : Alexion's Catalysts, Amgen's Prolia, Ultragenyx Borosu..
10/10 Seattle Genetics initiates mid-stage of tisotumab vedotin in cervical cancer,..
09/27 Janssen's Darzalex OK'd in Japan for multiple myeloma
08/29 Seattle Genetics and Genmab team up to develop ADC tisotumab vedotin
08/29 Johnson & Johnson's Darzalex Is An Emerging Threat To The Primacy Of Celgene'..
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | GEN | DK0010272202 | 4-Traders
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 1 511  DKK
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Burton Gordon Malkiel Independent Director
Anders Gersel Pedersen Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB14.75%12 912
GILEAD SCIENCES11.73%104 487
REGENERON PHARMACEUTICALS19.69%47 079
VERTEX PHARMACEUTICALS110.07%39 018
ACTELION23.81%29 869
EXELIXIS, INC.84.64%8 091